5-Aryl indanones and derivatives as non-steroidal progesterone receptor modulators
摘要:
Novel 5-aryl indanones, inden-1-one oximes, and inden-1-ols were synthesized and evaluated as progesterone receptor (PR) modulators using the T47D cell alkaline phosphatase assay. Both PR agonists and antagonists were achieved with appropriate 3- and 5-substitution from indanones and inden-1-ols while inden-1-one oximes provided only PR antagonists. Several compounds such as 10 and 11 demonstrated potent in vitro PR agonist potency similar to that of steroidal progesterone (1). In addition, a number of compounds (e. g., 12, 13, 17, 18) showed potent PR antagonist activity indicating the indanones and derivatives are promising PR modulator templates. (C) 2009 Elsevier Ltd. All rights reserved.
5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
申请人:Zhang Puwen
公开号:US20070066628A1
公开(公告)日:2007-03-22
Compounds of formula I are provided, wherein R
1
-R
9
and n are defined herein, and pharmaceutical compositions and kits containing these compounds.
Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I or formula II, wherein R
3
-R
5
, R
10
, and R
11
are defined herein.
5-Aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
申请人:Zhang Puwen
公开号:US20070066637A1
公开(公告)日:2007-03-22
Compounds of formula I, wherein R
1
-R
9
and n are defined herein, and pharmaceutical compositions and kits containing these compounds are provided.
Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I or formula II, wherein R
3
-R
5
, R
10
, and R
11
are defined herein.
5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
申请人:Zhang Puwen
公开号:US20070066675A1
公开(公告)日:2007-03-22
Compounds of formula I or II are provided, wherein R
1
—R
8
are defined herein, and pharmaceutical compositions and kits containing these compounds.
Also provides are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I, formula II, or formula III, wherein R
2
—R
4
and R
9
are defined herein.
Formation of 2,2-dimethylchroman-4-ones during the photoinduced rearrangement of some aryl 3-methyl-2-butenoate esters. A mechanistic insight
作者:Daniela Iguchi、Rosa Erra-Balsells、Sergio M. Bonesi
DOI:10.1016/j.tet.2016.02.039
日期:2016.4
Several aryl 3-methyl-2-butenoate esters upon irradiation lead to the formation of [1,3]-migrated photoproducts, phenol and, surprisingly 2,2-dimethylchroman-4-one derivatives. The starting photochemical reaction takes place from the singlet excited state of the ester and as a total mechanism two consecutive reaction pathways are proposed. The former involves the photo-Fries rearrangement of the esters
A systematic study of the reaction of a series of monosubstituted phenols 3 and 3-methylbut-2-enoic acid 4 in phosphorusoxychloride/zinc chloride revealed that the formation of 4-chromanones was strongly infuenced by the substituents and their position on the aromatic ring of the starting phenols.